SYF2 (pre-mRNA splicing factor) is a conserved nuclear protein with dual roles in spliceosome function and cell cycle regulation. As a core component of the Prp19 complex/NTC, SYF2 participates in multiple spliceosomal steps, including catalytic step 2 and post-mRNA release disassembly 1. During spliceosome disassembly, SYF2 docks with other factors to activate the RNA helicase DHX15 on U6 snRNA, initiating the termination of pre-mRNA splicing 1. Beyond splicing, SYF2 functions in transcription elongation by maintaining Prp19C occupancy and facilitating TREX recruitment to transcribed genes, coupling transcription to mRNA export 2. In nervous system development, SYF2 regulates microtubule dynamics and is upregulated during Schwann cell differentiation and migration, with knockdown causing disorganized microtubule structures 3. Clinically, SYF2 overexpression is associated with multiple human cancers. It is upregulated in epithelial ovarian cancer, hepatocellular carcinoma, and breast cancer, where elevated expression correlates with tumor grade, Ki-67 expression, and poor prognosis 456. SYF2 promotes cancer cell proliferation by regulating cell cycle progression at the G1/S checkpoint and may confer chemotherapy resistance 57. These findings suggest SYF2 as both a biomarker and potential therapeutic target in cancer.